Antidepressants That Suppress REM Sleep Improve ALS Survival
Antidepressants that suppress REM sleep are associated with improved survival in people with amyotrophic lateral sclerosis (ALS), according to research at ATS 2025.
Tag: neurological neuromuscular and neurodegenerative
All
Latest
Antidepressants That Suppress REM Sleep Improve ALS Survival
Antidepressants that suppress REM sleep are associated with improved survival in people with amyotrophic lateral sclerosis (ALS), according to research at ATS 2025.
Read More
Daytime Sleepiness Tied to Greater Dementia Risk for Female Seniors
A study published in Neurology found that women in their 80s who experienced increasing daytime sleepiness over five years had double the risk of developing dementia.
Read More
Sleep Apnea Contributes to Dementia Development
‘The results provide new evidence that clinicians and patients, when making decisions about testing for sleep apnea and treating it, should consider the possibility that untreated sleep apnea causes or exacerbates dementia.’
Read More
FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy
Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of Duchenne Muscular Dystrophy.
Read More
Traffic-Related Air Pollution Linked to Alzheimer’s Brain Changes
New research reveals a link between traffic-related air pollution and increased amyloid plaques in the brain, a key Alzheimer’s marker.
Read More
Blood Cancer Therapy May Treat Patients with Autoimmune Disorder Myasthenia gravis
Myasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in skeletal muscle, including muscles needed for respiration.
Read More
Sleep Apnea Patients Lacking Deep Sleep at Risk of Worse Brain Health
Researchers found that people who have sleep apnea and spend less time in deep sleep may be more likely to have brain biomarkers that have been linked to an increased risk of stroke, Alzheimer’s disease, and cognitive decline.
Read More
Surprising Neurological Symptoms of Long COVID Identified
A study of long COVID patients with persistent neurological symptoms were found to have differences in their immune cell profiles and autonomic dysfunction, according to new research.
Read More
Cognitive Dysfunction Differs in Long COVID Patients if They Were Hospitalized
Neurological symptoms, findings, and patterns of cognitive dysfunction differ between long COVID patients who were hospitalized during their acute infection and those who didn’t require hospitalization.
Read More
CHEST Updates Guideline for Managing Neuromuscular Weakness
The guideline contains 15 evidence-based recommendations, a good practice statement, and an ungraded consensus-based statement.
Read More
Spinal Cord ‘Atlas’ May Explain Cell Death in ALS
A spinal cord “atlas” offers clues about the biology of cells in the spinal cord that die off in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Read More
Zephyrx Joins ALS Research Study
Zephyrx, a leading provider of end-to-end remote respiratory monitoring, has joined forces with EverythingALS on a new study to find a diagnosis, treatment, and cure for Amyotrophic Lateral Sclerosis.
Read MorePossible Therapeutic Target for ‘Sporadic’ ALS
Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS).
Read More
Smoking Increases Risk of Severe COVID-19 Outcomes
Research published in PLoS ONE assessed the association of smoking with COVID-19 complications.
Read More
Flu Vaccination Linked to 40% Reduced Risk of Alzheimer’s Disease
People who received at least one influenza vaccine were 40% less likely than their non-vaccinated peers to develop Alzheimer’s disease over the course of four years, according to a new study from UTHealth Houston.
Read More
ALS Action Plan to Address Neurodegenerative Diseases
The FDA unveiled an ALS Action Plan for Rare Neurodegenerative Diseases, a five-year strategy for improving and extending the lives of people living with rare neurodegenerative diseases.
Read More
Experimental ALS Drug NU-9 Superior to Existing Pharmaceuticals
The experimental ALS drug NU-9 is more effective at treating amyotrophic lateral sclerosis than existing FDA-approved drugs for the disease, according to research from Northwestern University scientists published in Scientific Reports.
Read More
Serious Neurologic Symptoms Present in 13% of Hospitalized COVID-19 Patients
Nearly 13% of patients admitted for COVID-19 in the first year of the pandemic developed serious...
Read More
How Does Cannabis Use Affect Brain Health?
The American Heart Association says some scientific evidence exists to challenge the belief that smoking marijuana is harmless and questions remain about its impact on brain health.
Read More
Long COVID: Brain Stimulation Improves Cognitive Deficits
Long COVID patients benefit from brain stimulation using microcurrents to improve cognitive deficits, researchers report.
Read More
Improving Air Quality Tied to Slower Cognitive Decline in Women
Improvements in air quality are associated with slower cognitive decline in women, according to a new study published in Plos Medicine.
Read MoreSilencing This Faulty ALS Gene May Uncover Clues to Rare Forms
An experimental drug suppressed a mutated amyotrophic lateral sclerosis gene, offering a potential therapy for rare, aggressive forms of ALS caused by mutations in the fused in sarcoma (FUS) gene.
Read More
Neurological Effects of COVID-19
A new article published in Science highlights what is currently known about the effects of SARS-CoV-2 on the brain, the importance of increased research into the underlying causes of Long COVID, and possible ways to treat its symptoms.
Read More
Even Mild Cases of COVID-19 Leave a Mark on the Brain – But it’s Not Clear How Long it Lasts
With more than 18 months of the pandemic in the rearview mirror, researchers have been steadily gathering new and important insights into the effects of COVID-19 on the body and brain.
Read More